SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-157250"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-157250" > Effects of Denosuma...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003380naa a2200469 4500
001oai:DiVA.org:uu-157250
003SwePub
008110822s2011 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1572502 URI
0247 a https://doi.org/10.1002/jbmr.4032 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Jamal, Sophie A.4 aut
2451 0a Effects of Denosumab on Fracture and Bone Mineral Density by Level of Kidney Function
264 c 2011-07-20
264 1b Wiley,c 2011
338 a print2 rdacarrier
520 a The incidences of osteoporosis and chronic kidney disease (CKD) both increase with increasing age, yet there is a paucity of data on treatments for osteoporosis in the setting of impaired kidney function. We examined the efficacy and safety of denosumab (DMAb) among subjects participating in the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6Months (FREEDOM) Study. We estimated creatinine clearance (eGFR) using Cockcroft-Gault and classified levels of kidney function using the modified National Kidney Foundation classification of CKD. We examined incident fracture rates; changes in bone mineral density (BMD), serum calcium, and creatinine; and the incidence of adverse events after 36 months of follow-up in subjects receiving DMAb or placebo, stratified by level of kidney function. We used a subgroup interaction term to determine if there were differences in treatment effect by eGFR. Most (93%) women were white, and the mean age was 72.3 +/- 5.2 years; 73 women had an eGFR of 15 to 29mL/min; 2817, between 30 to 59mL/min; 4069, between 60 to 89mL/min, and 842 had an eGFR of 90mL/min or greater. None had stage 5 CKD. Fracture risk reduction and changes in BMD at all sites were in favor of DMAb. The test for treatment by subgroup interaction was not statistically significant, indicating that treatment efficacy did not differ by kidney function. Changes in creatinine and calcium and the incidence of adverse events were similar between groups and did not differ by level of kidney function. It is concluded that DMAb is effective at reducing fracture risk and is not associated with an increase in adverse events among patients with impaired kidney function.
653 a impaired kidney function
653 a denosumab
653 a fractures
653 a bone mineral density
653 a MEDICINE
653 a MEDICIN
7001 a Ljunggren, Östenu Uppsala universitet,Institutionen för medicinska vetenskaper4 aut0 (Swepub:uu)osteljun
7001 a Stehman-Breen, Catherine4 aut
7001 a Cummings, Steven Ron4 aut
7001 a McClung, Michael R.4 aut
7001 a Goemaere, Stefan4 aut
7001 a Ebeling, Peter R.4 aut
7001 a Franek, Edward4 aut
7001 a Yang, Yu-ching4 aut
7001 a Egbuna, Ogo I.4 aut
7001 a Boonen, Steven4 aut
7001 a Miller, Paul D.4 aut
7102 a Uppsala universitetb Institutionen för medicinska vetenskaper4 org
7730 t Journal of Bone and Mineral Researchd : Wileyg 26:8, s. 1829-1835q 26:8<1829-1835x 0884-0431x 1523-4681
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-157250
8564 8u https://doi.org/10.1002/jbmr.403

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy